Leukapheresis Market Trends

Growth Drivers

• Growing Demand for Leukopaks in Clinical Research - Increased demand for leukopaks is also due to the growing interest in clinical trials involving immunotherapies and other cell-based treatments. Leukopads are comprised of a single selection of white blood cells essential for many types of medical research, including immunology, drug development, and cellular therapy. In addition, the leukapheresis market growth is being driven by an increasing number of advanced leukopaks launched for R&D activities. For instance, The Microbubble Leukopak Human T Cell Isolation research-use-only kit from Akadeum Life Sciences, Inc., a leader in buoyancy-based cell separation technology worldwide, has been released. This product is the outcome of successful external user data collected from early adopters.
• Growing Cases of Blood-related Disorders - The growth of the leukapheresis market is being driven by a growing number of patients with blood-related disorders. In the treatment of various blood leukemic disorders such as leukemia, lymphoma, and myeloma, apheresis is an important procedure. For instance, in 2020, there were 176,404 new cases of multiple myeloma diagnosed globally.  Leukapheresis assists in the management of disease symptoms, reducing complications and improving patients' outcomes by selective removal of certain blood components. The development of new treatments and approaches is also driven by the increasing knowledge of blood-related disorders, as well as advances in medical research. Consequently, demand for leukapheresis procedures is growing as the incidence of blood disorders increases.
• Increasing Clinical Trials for CAR T-cell Therapy - CAR T-cell therapy is a rapidly evolving field, with ongoing research aimed at optimizing treatment efficacy, expanding indications, and reducing side effects. For instance, in preclinical trials, a novel form of CAR T-cell therapy that was developed by researchers at a University specifically targeted cancer cells while preserving healthy cells. This could potentially lower the risk of harmful side effects from this ground-breaking cancer treatment. The cancer of the plasma cells located in the bone marrow of the body, known as multiple myeloma, was the reason behind the creation of the cells. Therefore, the increasing incidences of cancer, particularly hematologic malignancies such as leukemia and lymphoma, fuel the demand for innovative treatment options like CAR T-cell therapy.

Challenges

• High Costs of the Procedures - Because leukapheresis treatments and related products can be costly, patients and healthcare facilities may not be able to obtain them, especially in areas with poor financial resources or insufficient healthcare infrastructure. Therefore, the high costs of the products may hinder the growth of the leukapheresis market.
• Lack of Skilled Technical professionals may Hamper the Growth of the Market
• Blood Transfusion Safety in Developing Countries may Hinder leukapheresis market Growth